PainReform Ltd's PRF-110 Demonstrates Superior In-Vitro Release Rates, Revolutionizing Post-Surgical Pain Management. In a groundbreaking development that could significantly alter the landscape of post-surgical pain management, PainReform Ltd (NASDAQ: PRFX) has unveiled compelling results from recent studies showcasing the superior in-vitro release (IVR) rates of its innovative product, PRF-110, compared to the industry-l...
$PainReform(PRFX.US)$EXCLUSIVE: PainReform Tells Benzinga 'Over a 72-hour Industry-standard Duration, and Extending to 96 Hours, PRF-110 Exhibited Remarkably Higher Rates of Analgesic Drug Release Compared to a Market-leading Post-surgical Pain Product'
$PainReform(PRFX.US)$PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief 2 MINUTES AGO, 8:30 AM EST VIA GLOBENEWSWIRE
PainReform股票讨论区
NEWS
PainReform Announces Closing of $4 Million Public Offering
NEWS
PainReform Announces Pricing of $4 Million Public Offering
In a groundbreaking development that could significantly alter the landscape of post-surgical pain management, PainReform Ltd (NASDAQ: PRFX) has unveiled compelling results from recent studies showcasing the superior in-vitro release (IVR) rates of its innovative product, PRF-110, compared to the industry-l...
2 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
暂无评论